Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.

Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS.

Clin Cancer Res. 2017 Jul 1;23(13):3277-3284. doi: 10.1158/1078-0432.CCR-16-2299. Epub 2016 Dec 30.

2.

National cancer clinical trials: children have equal access; adolescents do not.

Bleyer WA, Tejeda H, Murphy SB, Robison LL, Ross JA, Pollock BH, Severson RK, Brawley OW, Smith MA, Ungerleider RS.

J Adolesc Health. 1997 Dec;21(6):366-73.

PMID:
9401854
3.

Equal participation of minority patients in U.S. national pediatric cancer clinical trials.

Bleyer WA, Tejeda HA, Murphy SB, Brawley OW, Smith MA, Ungerleider RS.

J Pediatr Hematol Oncol. 1997 Sep-Oct;19(5):423-7.

PMID:
9329463
4.

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute.

Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R.

J Clin Oncol. 1997 Jul;15(7):2736-43.

PMID:
9215848
5.

Assessing whether to perform a confirmatory randomized clinical trial.

Parmar MK, Ungerleider RS, Simon R.

J Natl Cancer Inst. 1996 Nov 20;88(22):1645-51.

PMID:
8931608
6.

Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials.

Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS, Friedman MA, Brawley OW.

J Natl Cancer Inst. 1996 Jun 19;88(12):812-6.

PMID:
8637047
7.

Dose Intensity of Chemotherapy for Childhood Cancers.

Smith M, Abrams J, Trimble EL, Ungerleider RS.

Oncologist. 1996;1(5):293-304.

8.

Representation of older patients in cancer treatment trials.

Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA.

Cancer. 1994 Oct 1;74(7 Suppl):2208-14.

PMID:
8087794
9.

Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.

Smith MA, Rubinstein L, Ungerleider RS.

Med Pediatr Oncol. 1994;23(2):86-98. Review.

PMID:
8202047
10.

Neoadjuvant therapy in cancer treatment.

Trimble EL, Ungerleider RS, Abrams JA, Kaplan RS, Feigal EG, Smith MA, Carter CL, Friedman MA.

Cancer. 1993 Dec 1;72(11 Suppl):3515-24. Review.

PMID:
8242583
11.

Children and cancer. A perspective from the Cancer Therapy Evaluation Program, National Cancer Institute.

Smith M, Simon R, Cain D, Ungerleider RS.

Cancer. 1993 May 15;71(10 Suppl):3422-8.

PMID:
8490893
12.

Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.

Smith MA, Rubinstein L, Cazenave L, Ungerleider RS, Maurer HM, Heyn R, Khan FM, Gehan E.

J Natl Cancer Inst. 1993 Apr 7;85(7):554-8.

PMID:
8455202
13.

Clinical trials referral resource.

Cheson BD, Ungerleider RS.

Oncology (Williston Park). 1993 Mar;7(3):55-6, 59. No abstract available. Erratum in: Oncology (Huntingt) 1993 Apr;7(4):38.

PMID:
8452780
14.

Clinical trials referral resource. High priority trials--III. Breast cancer.

Cheson BD, Ungerleider RS.

Oncology (Williston Park). 1992 Dec;6(12):46-50. No abstract available.

PMID:
1334690
15.

Clinical trials referral resource.

Cheson BD, Ungerleider RS.

Oncology (Williston Park). 1992 Nov;6(11):30, 32, 34-6. No abstract available.

PMID:
1332740
16.

Clinical trials referral resource. High Priority Trials.

Cheson BD, Ungerleider RS.

Oncology (Williston Park). 1992 Oct;6(10):57-8. No abstract available.

PMID:
1390015
17.

Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma.

Smith MA, Ungerleider RS, Horowitz ME, Simon R.

J Natl Cancer Inst. 1991 Oct 16;83(20):1460-70.

PMID:
1833556
18.

Sex, trials, and datatapes.

Ungerleider RS, Friedman MA.

J Natl Cancer Inst. 1991 Jan 2;83(1):16-7. No abstract available.

PMID:
1984514
19.

A comparison of four staging systems for localized and regional neuroblastoma: a report from the Childrens Cancer Study Group.

Evans AE, D'Angio GJ, Sather HN, de Lorimier AA, Dalton A, Ungerleider RS, Finklestein JZ, Hammond GD.

J Clin Oncol. 1990 Apr;8(4):678-88.

PMID:
2313336
20.

A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.

Messerschmidt GL, Makuch R, Appelbaum F, Ungerleider RS, Abrams R, O'Donnell J, Holohan TV, Fontana J, Wright D, Anagnou NP, et al.

Cancer. 1988 Aug 15;62(4):795-801.

PMID:
3293762
21.

Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.

Grem JL, Hoth DF, Leyland-Jones B, King SA, Ungerleider RS, Wittes RE.

J Clin Oncol. 1988 Feb;6(2):351-79. Review.

PMID:
3276827
22.

Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults.

Holcenberg JS, Tutsch KD, Earhart RH, Ungerleider RS, Kamen BA, Pratt CB, Gribble TJ, Glaubiger DL.

Cancer Treat Rep. 1986 Jun;70(6):703-9.

PMID:
3089595
23.

Tolerance to antineoplastic agents in children and adults.

Marsoni S, Ungerleider RS, Hurson SB, Simon RM, Hammershaimb LD.

Cancer Treat Rep. 1985 Nov;69(11):1263-9. No abstract available.

PMID:
2418966
24.

Phase I trial of mitoxantrone in children.

Ungerleider RS, Pratt CB, Vietti TJ, Holcenberg JS, Kamen BA, Glaubiger DL, Cohen LF.

Cancer Treat Rep. 1985 Apr;69(4):403-7.

PMID:
3857968
25.

Pediatric cancer and nutrition workshop: introductory comments.

Ungerleider RS, DeWys WD, Fink DJ.

Cancer Res. 1982;42(2 Suppl):698s. No abstract available.

26.
27.

Working conference on neuroblastoma treatment trials.

Ungerleider RS.

Cancer Treat Rep. 1981 Jul-Aug;65(7-8):719-23. No abstract available.

PMID:
7248989
28.

The relative tolerance of children and adults to anticancer drugs.

Glaubiger DL, von Hoff DD, Holcenberg JS, Kamen B, Pratt C, Ungerleider RS.

Front Radiat Ther Oncol. 1981;16:42-9. No abstract available.

PMID:
6460663
29.

Antitumor activity of chlorozotocin (NSC-178748).

Ungerleider RS.

Cancer Treat Rev. 1980 Dec;7(4):191-5. No abstract available.

PMID:
6452199
30.

Lack of predictive value of antileukocyte antibody screening in granulocyte transfusion therapy.

Ungerleider RS, Appelbaum FR, Trapani RJ, Deisseroth AB.

Transfusion. 1979 Jan-Feb;19(1):90-4.

PMID:
432918
31.

Pretreatment of filtration leukapheresis donors with colchicine.

Wright DG, Ungerleider RS, Gallin JI, Deisseroth AB.

Blood. 1978 Oct;52(4):783-92. No abstract available.

32.

Endodermal sinus tumor: the Stanford experience and the first reported case arising in the vulva.

Ungerleider RS, Donaldson SS, Warnke RA, Wilbur JR.

Cancer. 1978 Apr;41(4):1627-34.

PMID:
639017

Supplemental Content

Loading ...
Support Center